Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope: Pre-Surgery combo shrinks breast tumors, spares healthy tissue

NCT ID NCT01750073

First seen Nov 18, 2025 · Last updated May 01, 2026 · Updated 24 times

Summary

This study tests whether giving chemotherapy (paclitaxel and cyclophosphamide) with or without the targeted drug trastuzumab before surgery can shrink breast tumors and reduce the amount of healthy tissue that needs to be removed. It includes 92 women with early-stage or locally advanced breast cancer that is either HER2-positive or HER2-negative. The main goals are to check side effects and see how many patients have no cancer left at surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHI Health Saint Francis

    Grand Island, Nebraska, 68803, United States

  • Nebraska Medicine-Bellevue

    Bellevue, Nebraska, 68123, United States

  • Nebraska Medicine-Village Pointe Cancer Center

    Omaha, Nebraska, 68118, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

Conditions

Explore the condition pages connected to this study.